Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

Association of socioeconomic and clinical factors with overall survival in immunotherapy-eligible stage III non-small cell lung cancer following definitive chemoradiation.

View Full Paper
Ask AI
Bookmark
Share

Authors

CHChaewon HwangJFJincong Q. FreemanDRDaniela Reyes

Discussion

Loading...

Member takes

Overview

Retrospective analysis explores survival in immunotherapy-eligible lung cancer patients, highlighting access disparities.

Key Points

  • To evaluate the impact of socioeconomic and clinical factors on overall survival in immunotherapy-eligible stage III non-small cell lung cancer after chemoradiation.
  • Retrospective analysis of National Cancer Database patients aged ≥18 with stage III NSCLC from 2018-2020.
  • Examined variables included race/ethnicity, insurance, facility type, and comorbidity index among others.
  • Survival was assessed using Kaplan-Meier and multivariable Cox regression analysis for overall survival.
  • Median overall survival was significantly higher with immunotherapy (42.1 vs 22.3 months, P<.001).
  • Insurance type and treatment facility affected survival, with privately insured patients showing higher median OS (41.7 months, P<.001).
  • Immunotherapy receipt was associated with lower all-cause mortality (HR 0.53; 95% CI 0.51-0.56).

Cite This Study

Hwang et al. (2026) studied this question.

synapsesocial.com/papers/6a192df7fab5b468c4416f43https://doi.org/10.1200/jco.2026.44.16_suppl.1522
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of immunotherapy era on survival in stage IV non–small cell lung cancer.2026
  2. 2Socioeconomic focus in neoadjuvant chemoimmunotherapy: An analysis of pathologic complete response and overall survival in clinical stage II-III NSCLC patients.2026
  3. 3Sequencing strategy of immunotherapy with chemoradiotherapy in stage III non–small cell lung cancer: A pooled analysis of prospective trials.2026
  4. 4Feasibility of induction chemoimmunotherapy (ID chemo-IO) followed by chemoradiation for locally advanced unresectable non-small cell lung cancer (NSCLC).2024
  5. 5Multi-institution real world analysis of patients with non-small cell lung cancer (NSCLC) treated with standard of care (SOC) neoadjuvant chemo-immunotherapy (chemoIO).2024 · 1 citations